Adaptimmune Therapeutics Plc - Asset Resilience Ratio
Adaptimmune Therapeutics Plc (ADAP) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Adaptimmune Therapeutics Plc's Asset Resilience Ratio has changed over time. Check Adaptimmune Therapeutics Plc (ADAP) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Adaptimmune Therapeutics Plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ADAP company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Adaptimmune Therapeutics Plc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Adaptimmune Therapeutics Plc Industry Peers by Asset Resilience Ratio
Compare Adaptimmune Therapeutics Plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Adaptimmune Therapeutics Plc (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Adaptimmune Therapeutics Plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 24.58% | $60.47 Million | $245.96 Million | +23.54pp |
| 2023-12-31 | 1.04% | $2.95 Million | $282.62 Million | -28.32pp |
| 2022-12-31 | 29.36% | $96.57 Million | $328.92 Million | -17.41pp |
| 2021-12-31 | 46.78% | $219.63 Million | $469.55 Million | -22.23pp |
| 2020-12-31 | 69.01% | $311.33 Million | $451.14 Million | +47.46pp |
| 2019-12-31 | 21.55% | $39.13 Million | $181.54 Million | -27.86pp |
| 2018-12-31 | 49.42% | $136.75 Million | $276.74 Million | +5.23pp |
| 2017-12-31 | 44.18% | $124.22 Million | $281.15 Million | +34.51pp |
| 2016-12-31 | 9.68% | $22.69 Million | $234.51 Million | -8.71pp |
| 2015-12-31 | 18.39% | $55.30 Million | $300.68 Million | 0.00pp |
| 2014-12-31 | 18.39% | $55.30 Million | $300.68 Million | -80.68pp |
| 2013-12-31 | 99.07% | $55.00 Million | $55.52 Million | -- |
About Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatmen… Read more